(Q26747139)

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Clonal dissection of the human memory B-cell repertoire following infection and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Viral receptor-binding site antibodies with diverse germline origins

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

A New Way to Diversify Antibodies by DNA Transposition

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

To dream the impossible dream: universal influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Self-assembling protein nanoparticles in the design of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Receptors and immune sensors: the complex entry path of human cytomegalovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Cross-neutralization of four paramyxoviruses by a human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Proof of principle for epitope-focused vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Accurate design of co-assembling multi-component protein nanomaterials

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Rapid development of broadly influenza neutralizing antibodies through redundant mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Structure and immune recognition of trimeric pre-fusion HIV-1 Env.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

The promise and challenge of high-throughput sequencing of the antibody repertoire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Universal influenza virus vaccines: need for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Vaccine prevention of maternal cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

A highly conserved neutralizing epitope on group 2 influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Highly Conserved Protective Epitopes on Influenza B Viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Immune history profoundly affects broadly protective B cell responses to influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

High preexisting serological antibody levels correlate with diversification of the influenza vaccine response

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

1 reference

7 January 2021

Broadly neutralizing antiviral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Focused antibody response to influenza linked to antigenic drift

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.COI.2016.06.001

7 January 2021